Open AccessA novel signature based on immune‐related gene pairs and clinical features to predict prognosis and treatment effect in “driver gene negative” lung adenocarcinoma
Author(s) -
Cai Heyuan,
Yang Haoshuai,
Shan Shichao,
Lei Yiyan,
Zou Jianyong,
Zhu Ying,
Luo Honghe
Publication year - 2022
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.4577
Subject(s) - nomogram , immune system , oncology , adenocarcinoma , gene , gemcitabine , medicine , lung cancer , immunotherapy , proportional hazards model , biology , chemotherapy , cancer , immunology , cancer research , genetics
Abstract Objective Examining the role of immune‐related genes (IRGs) in “driver gene negative” lung adenocarcinoma (LUAD) may provide new ideas for the treatment and study for this LUAD subgroup. We aimed to find the hub immune‐related gene pairs can stratify the risk of “driver‐gene‐negative” LUAD. Materials and Methods IRGs were identified according to ImmPort database based on RNA sequencing results of tumors and normal tissues from 46 patients with “driver gene negative” LUAD at The First Affiliated Hospital of Sun Yat‐sen University and cyclically singly paired as immune‐related gene pairs (IRGPs). Multivariate Cox analysis was used to construct an immune risk model and a prognostic nomogram combining was also been developed. Immune microenvironment landscape described by CIBERSORT and drug sensitivity calculated by pRRophetic algorithm were used to explore possible treatment improvements. Results A novel immune risk model with 5‐IRGPs (CD1A|CXCL135, CD1A|S100A7L2, IFNA7|CMTM2, IFNA7|CSF3, CAMP|TFR2) can accurately distinguish patients in the high‐ and low‐risk groups. Risk score act as an independent prognostic factor and is related to clinical stage. There are significant differences in tumor immune microenvironment and PD‐1/PD‐L1/CTLA‐4 expression between groups. The low‐risk patient may benefit more from the commonly used chemotherapy regimens such as gemcitabine and paclitaxel. Conclusion This study constructed 5‐IRGPs as a reliable prognostic tool and may represent genes pairs that are potential rationale for choice of treatment for “driver gene negative” LUAD.